Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic agent for thrombosis

A technology of thrombosis and therapeutic agents, applied in the field of thrombosis therapeutic agents, can solve problems such as unknown degree, no effect, and unapproved thrombosis therapeutic agents, and achieve the effect of reducing side effects and strong antithrombotic effect

Inactive Publication Date: 2008-03-19
KOWA CO LTD +1
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

HMG-CoA reductase inhibitors are known to have a strong inhibitory effect on HMG-CoA reductase and are useful as agents for lowering blood cholesterol, but they have not been approved as therapeutic agents for thrombosis
In addition, in the above-mentioned gazette, there is no specific description of the effects of such combined administration, and the extent thereof is also unclear.
Furthermore, there is no description about the action and effect of the combined administration of pitavastatins (Patent Documents 2 and 3), which are one of the HMG-CoA reductase inhibitors, and aspirin.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for thrombosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Effects of combined administration of aspirin and pitavastatin calcium on whole blood coagulation time (r+k value) (anticoagulant effect) and maximum clot formation ability (MA) (thrombolysis promoting effect)

[0035] The effects of administration of aspirin and pitavastatin calcium on whole blood clotting time (r+k value) and maximum clot formation ability (MA) were measured according to the following method (items 1 to 4 below) , the results are shown in item 5 (r, reaction time: reaction time; k, clotting time: coagulation time; MA, Maximal Amplitude: maximum amplitude).

[0036] 1. Experimental animals and feeding environment

[0037] For the test, 6-week-old Hartley male guinea pigs (Nippon SLC Co., Ltd.) were used. During the whole experiment period, they were kept in a breeding room with a light-dark cycle (bright period formed by indoor light: 7:00 am to 7:00 pm), temperature 23±3°C, and humidity 55±15%, and they were allowed to ingest freely. Solid feed (RC4...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a therapeutic agent for thrombosis, in particular to a therapeutic agent for thrombosis effective both in inhibiting blood coagulation and in dissolving thrombus. The therapeutic agent for thrombosis is characterized by containing pitavastatins and aspirin.

Description

technical field [0001] The present invention relates to a therapeutic agent for thrombosis, in particular to a therapeutic agent for thrombosis effective both in inhibiting blood coagulation and in dissolving thrombus. Background technique [0002] In thrombosis, due to the increased platelet aggregation function, the improvement of blood coagulation function caused by the activation of blood coagulation factors, and the decrease of thrombus dissolution function act alone or together, thrombus is formed in arterial or venous blood vessels, resulting in poor blood circulation . The resulting ischemia reduces the supply of oxygen and nutrients in the peripheral tissues including the brain, heart and other organs, which can easily lead to the onset of fatal symptoms such as cerebral infarction and myocardial infarction. Therefore, it is considered that the treatment of thrombosis is very important among diseases in the above-mentioned fields. [0003] Currently, various agent...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/47A61K31/616A61P7/02
Inventor 横山融青木太郎
Owner KOWA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com